A qbd-based Strategy for the Formulation of Paclitaxel-loaded Solid Lipid Nanoparticles in Conjunction with Herbal Extracts for Breast Cancer

This Study used a Quality by Design strategy to produce paclitaxel-encapsulated solid lipid nanoparticles (SLNs) with herbal extracts to improve the safety and efficacy of breast cancer treatment. The solvent emulsification and ultrasonication-prepared SLNs are utilized to increase paclitaxel solubility, overcome chemoresistance, and reduce toxicity. Proper examination of preparation parameters aided in establishing better control over nanoparticle size, encapsulation percentage, and release rate. When coupled with antitumor herbs, the improved nanocarriers exhibited stability, high paclitaxel loading, sustained release, and enhanced anticancer properties. To summarize, this study demonstrates the co-delivery of breast cancer treatment by encapsulating chemotherapeutic medications with natural substances using targeted SLNs. Pharmacotherapy benefits from nanoformulation because it increases the bioavailability and specificity of tumor tissue while lowering overall toxicity. Other chemorefractory cancers may be more amenable to this integrated strategy, which could also lead to improved patient concordance and therapeutic efficacy through combinational drug delivery. Larger-scale production and preclinical research could open the door to the clinical application of QbD Design nanoparticles in the fight against lethal carcinoma.